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Abstract 
Objective: To determine the underlying monogenic basis for sudden infant death syndrome (SIDS) 
with an exome-wide focus.   
Study Design: A cohort of 427 unrelated SIDS cases (257 males; average age = 2.7 ± 1.9 months) 
underwent whole exome sequencing (WES).  Exome-wide rare variant analyses were carried out 
with 278 European ancestry SIDS cases (173 males; average age = 2.7 ± 1.98 months) and 973 
ethnic-matched controls based on six genetic models. Ingenuity Pathway Analysis  was also 
performed.  The cohort was collected in collaboration with coroners, medical examiners, and 
pathologists by St George's University of London, UK and Mayo Clinic, Rochester, Minnesota, 
USA.  WES was performed at the Genomic Laboratory, Kings College London, UK or Mayo 
Clinic’s Medical Genome Facility, Rochester, Minnesota.  
Results:  While no exome-wide significant (p<2.5x10-6) difference in burden of ultra-rare variants 
was detected for any gene, 405 genes had a higher prevalence (p<0.05) of ultra-rare non-
synonymous variants among cases with seventeen genes at p<0.005.  Some of these potentially 
overrepresented genes may represent biologically plausible novel candidate genes for the 
monogenic basis for some of SIDS.  The top canonical pathway identified was glucocorticoid 
biosynthesis (p=0.01).   
Conclusions: The lack of exome-wide significant genetic associations indicates an extreme 
heterogeneity of etiologies underlying SIDS. Our approach to understanding the genetic 
mechanisms of SIDS has far reaching implications for the SIDS research community as a whole 
and may catalyze new evidence-based SIDS research across multiple disciplines.  Perturbations in 
glucocorticoid biosynthesis may represent a novel SIDS-associated biological pathway for future 
SIDS investigative research.  
Keywords: inherited cardiac conditions, molecular autopsy, sudden infant death syndrome, 
whole exome sequencing  
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Introduction  
Sudden Infant Death Syndrome (SIDS) is the sudden unexpected death of an infant less than 1 year 
of age, which remains unexplained despite comprehensive clinical and pathological 
investigations.[1] SIDS represents 70-80% of all sudden unexpected infant deaths with an incidence 
of 0.4/1000 live births in the UK and 0.5/1000 live births in the USA.[2, 3] The peak incidence 
occurs between 2 – 4 months of age and is more common in males. It is associated commonly with 
environmental risk factors such as co-sleeping or prone sleeping position.[4] Despite successful 
targeted risk reduction campaigns, the number of SIDS cases have plateaued, and SIDS, also 
referred to as sudden unexplained infant death (SUID) remains the leading cause of post-neonatal 
mortality.[4]  
A triple-risk model for SIDS suggest the convergence of the vulnerable infant in the setting 
of exogenous stressors occurring in a critical development period.[5]  Although many 
pathophysiologic theories have been proposed, decisive pathogenic substrates/mechanisms 
triggering an infant’s sudden demise remain unclear.[6-9] Several studies have implicated both 
common and rare genetic variants involved in autonomic function, neurotransmission, energy 
metabolism, response to infection, and cardiac repolarization.[10-14]   Potentially lethal inherited 
genetic heart diseases including long QT syndrome (LQTS), Brugada syndrome (BrS), 
catecholaminergic polymorphic ventricular tachycardia (CPVT), and hypertrophic cardiomyopathy 
(HCM) have been implicated as monogenic causes for a small proportion (< 10%) of SIDS 
cases.[10, 13, 15-27] [28]   
However, less than 100 investigations of genetic variation in population-based SIDS cohorts 
have been published to date, largely based on hypothesis-driven, candidate gene/pathway 
approaches that recognize established environmental risk factors for SIDS, with an average cohort 
size of just 125 SIDS cases.[13]   Although one may postulate that the genetics of SIDS is most 
likely multigenic and complex, no studies have attempted to elucidate the underlying genetic basis 
in a single SIDS cohort across multiple biological pathways in an unbiased manner.  Here, using 
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whole exome sequencing (WES), we conducted an exome-wide analysis of rare protein-altering 
variation followed by biological Ingenuity Pathway Analysis (IPA) in a cohort of nearly 300 
unrelated Caucasian SIDS cases.   
Methods 
Study Population 
As previously described, the SIDS cohort (N=427) consisted of 95 coroners’ cases from the United 
Kingdom (UK; London, Sheffield, Edinburgh and Bristol) and 332 coroner/medical 
examiner/forensic pathologist-referred cases collected from six ethnically and geographically 
diverse United States (US) populations.[28]  Because of the lack of uniformity in procedures and 
reporting between medical examiner offices in the US, differences in protocols may exist.  
Nonetheless, both gross and histological examinations of all major organs were performed and all 
cases satisfied our enrolment criteria that included 1) sudden unexplained death of an infant < 1 
year of age, 2) European descent, and 3) a comprehensive negative medico-legal autopsy including 
a negative toxicology screen and death scene investigation. Infants, clearly demonstrated to have 
experienced asphyxia or specific disease causing death, were excluded.  Ethnicity was self-reported 
by the referring coroner/medical examiner.  This anonymous necropsy study only had limited 
medical information such as the sex, ethnicity, age at the time of death, and sleep position available. 
This study complies with the Declaration of Helsinki; locally appointed ethics committees including 
Mayo Clinic’s Institutional Review Board have approved the research protocol.  
Control Population 
973 Caucasian control exomes (509 females, 464 males) from the ICR1000 UK exome sequencing 
of the 1958 Birth Cohort study were included for analysis.[29] As previously reported, exome 
sequencing was performed using the Illumina TruSeq and Illumina instruments.[29] 
Whole Exome Sequencing 
Genomic DNA isolated from each SIDS case underwent WES at the KCL-GSTT Biomedical 
Research Centre Genomics Platform, London, UK or Mayo Clinic’s Medical Genome Facility, 
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Rochester, Minnesota as described previously.[28] Cases were excluded from further analysis if < 
75% of the Gencode defined protein coding exome was covered by < 20 reads. A set of 3847 
common variants located outside of regions of the genome, where there is extensive linkage 
disequilibrium, were used to estimate relatedness within the study cohort. To avoid potential 
confounding due to population stratification, ancestry estimation was undertaken using the first two 
dimensions of Multidimensional Scaling (MDS) using Euclidean distance undertaken with the King 
software package.  Quality control metrics excluded 7 cases.[28]  The resulting SIDS cases (N = 
278) and European controls (N = 973) that formed a homogeneous cluster on the first two principal 
components were included in the case-control rare variant analysis.[28]  
Exome-Wide Rare Variant Analysis 
The 278 European Caucasian SIDS cases and 973 ethnic-matched controls underwent a case-
control simple collapsing exome-wide rare variant association analysis using the Efficient and 
Parallelizable Association Container Toolbox (EPACTS).[30] Cases and controls were coded with a 
binary indicator according to the presence/absence of a “qualifying” variant in each gene based on 
six genetic models: dominant non-synonymous (amino acid altering), dominant non-synonymous-
combined annotation dependent depletion (CADD ≥ 20: equivalent to a probability of 0.99 that the 
variant has a functional impact.[31]), dominant putative loss-of-function (i.e. nonsense, frame-shift, 
and canonical splice-site errors), recessive non-synonymous, recessive non-synonymous-CADD ≥ 
20, and recessive putative loss-of-function.   
  For all models, only “ultra-rare” variants with a minor allele frequency (MAF) < 0.00005 
(1:20,000 alleles) derived from the Exome Aggregation Consortium (ExAC)[32] were included.   
Deviation from the null model of no excess of rare variation in cases was evaluated with a one-
tailed Fisher’s exact test. Despite being too stringent, a Bonferroni-adjusted p-value threshold of < 
2.5x10-6 was considered as exome-wide significant.  
Ingenuity Pathway Analysis    
An Ingenuity Pathway Analysis (IPA) was used to analyze a list of 405 genes (p-value<0.05) 
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obtained by performing an exome-wide rare variant comparative analysis between European SIDS 
cases and ethnic-matched controls. IPA is a web-based tool that is used for discovery and 
visualization of significant pathways and networks, and close correlations with disease and 
functional classes. Data were analyzed with QIAGEN’s Ingenuity® Pathway Analysis (IPA®, 
QIAGEN Redwood City, www.qiagen.com/ingenuity) using default analysis settings.[33]   
Statistics 
Categorical variables were expressed as absolute numbers and percentage, and compared with 
Fisher’s exact or Chi-square tests.  Probability values were based on two-sided tests considered 
significant at P<0.05. Analysis was conducted with SPSS version 18.0 software (SPSS Chicago III).  
The significance of the association between the data set (i.e. 405 “SIDS genes”) and the IPA 
canonical pathway was measured in 2 ways: 1) A ratio of the number of genes from the data set that 
map to the pathway divided by the total number of genes that map to the canonical pathway.  2) 
Fisher’s exact test right-tailed was used to calculate a p-value determining the probability that the 
association between the genes in the dataset and the canonical pathway is explained by chance 
alone.[33]  
Results 
Demographics 
The cohort consisted of 278 cases (173 male infants, 105 female infants; average age = 2.7 ± 1.98 
months). The epidemiologically high risk age group of 2–4 months (55.4%) and male gender 
(62.9%) accounted for the majority of the cases. Sleep characteristics were known in 60% of the 
cohort (Table 1).   
Exome-Wide Rare Variant Analysis 
Exome-wide rare variant analyses were performed with the 278 European ancestry cases and 973 
matched controls. None of the estimated 20,000 genes within the human genome were associated 
with SIDS when considering an exome-wide significant p-value threshold of < 2.5x10-6 with any of 
the 6 aforementioned inheritance models.   
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There were 405 genes with potential case:control, ultra-rare (MAF < 0.00005), non-
synonymous variant over-representation at p < 0.05 threshold (Table 2; Online) with 17 genes 
reaching  p<0.005 (Table 3).  Online Mendelian Inheritance in Man (OMIM) disease[34] and 
PathCards SuperPathway [35] associations for each gene is listed in Table 4; Online.  The 
prevalence of ultra-rare, non-synonymous variants with a CADD score > 20 was higher (p<0.005) 
in cases versus controls in 10 genes (Table 5; Online).  Some of these genes may represent novel, 
biologically plausible candidate genes for SIDS.  For example, 6/278 (2.2%) SIDS cases hosted an 
NR3C2 (MIM: 600983) variant compared to only 2/973 (0.21%) controls (p=0.000778).  Variants in 
the CHRM3 (MIM: 118494)-encoded cholinergic receptor muscarinic-3 were over-represented in 
SIDS cases (4/278 [1.4%]) compared to controls (0/973, p=0.002), and LHX9 (MIM: 606066) 
variants were also over-represented in SIDS cases (5/278 [1.8%]) compared to controls (0/973, 
p=0.000527).   
Ingenuity Pathway Analysis (IPA) 
IPA was performed on the aforementioned 405 genes from our dominant non-synonymous ultra-rare 
variants analysis with a p-value <0.05.  IPA identified 5 canonical pathways with a p-value < 0.05 
(Table 6).    The top canonical pathway involved glucocorticoid biosynthesis (p=0.0107, Table 6). 
Of the 8 genes within the glucocorticoid biosynthesis pathway, 2 genes (25%) were present among 
the 405 candidate genes.  Ultra-rare CYP17A1 ([MIM: 609300], 4/278 [1.4%] vs 1/973 [0.1%], 
p=0.0099), and CYP11B2 ([MIM: 124080], 6/278 [2.2%] vs 3/973 [0.3%], p=0.0052) non-
synonymous variants were both over-represented in the cases versus controls (p=0.0001 when 
considered together).  
Discussion 
This manuscript details the genetic insights gleaned from WES in the largest cohort of unrelated 
SIDS cases with the first ancestry matched case-control burden analysis of ultra-rare variants 
involving nearly 300 cases and 1000 healthy controls to identify potential novel monogenic causes 
for SIDS.   While no genes reached the very strict Bonferroni-corrected exome-wide significance 
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threshold of p< 2.5x10-6, 405 genes showed a potential over-representation of ultra-rare, non-
synonymous variants.  However, variants were observed in less than 2% of the SIDS cohort for 
90% of these 405 genes, thus confirming prior speculation that SIDS is a highly heterogeneous 
condition and likely results from a complex interplay of genetic and environmental factors rather 
than from a small number of highly penetrant monogenic disorders.  In addition, at the p-value 
threshold of p < 0.05, one might expect 1000 genes to surface as seemingly over-represented in 
cases just by chance (i.e. 20,000 genes divided by 20).  In other words, this study strongly suggests 
that the vast majority of SIDS is NOT monogenetically-mediated at least by ultra-rare genetic 
variation localizing to the 2% of the genetic code called the exome.  Although it remains to be 
confirmed or refuted, much of SIDS may not have any genetic component at all.  
Nevertheless, some of these genes identified are appealing pathobiologically and could 
represent novel, monogenic causes for a small minority of SIDS cases.  For example, there was 
potential over-representation (p<0.005) of NR3C2, CHRM3, and LHX9 variants in SIDS cases 
compared to controls.  These three genes may represent biologically plausible candidates for SIDS 
pathogenicity that could account independently for a small subset of SIDS cases (~2%).   
The NR3C2 gene encodes for a mineralocorticoid receptor that mediates aldosterone activity 
and is responsible for autosomal dominant pseudohypoaldosternism Type 1 (adPHA1) which is a 
rare disorder characterized by renal resistance to aldosterone, with salt-wasting, hyperkalemia, and 
metabolic acidosis[36].  If undetected and untreated, adPHA1 may present with neonatal lethality 
owing to sever hyponatremia, metabolic acidosis, or hyperkalemia-mediated arrhythmia and 
cardiorespiratory arrest.[37, 38]  Interestingly, conditional targeted cardiomyocyte over-expression 
of mineralocorticoid receptor  in mice lead to early sudden death without cardiac structural 
alteration as a result of prolonged ventricular repolarization and spontaneous and triggered 
ventricular arrhythmias associated with ion channel remodeling.[39]  
  The CHRM3 gene encodes for cholinergic receptor muscarinic 3 (M3-receptor).  Muscarinic 
acetylcholine receptors are G-protein-coupled receptors that play a key role in parasympathetic 
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acetylcholine neurotransmission for a variety of physiological functions within the brain, heart, and 
respiratory system.[40]  In the respiratory system, muscarinic M3-receptors mediate smooth muscle 
contraction for respiration.[40]  In the heart, M3-receptors may play a role in the regulation and 
maintenance of cardiac function.[41, 42]  The M3-receptors activate the delayed rectifying 
potassium current IKM3 to participate in the regulation of heart rate, cardiac resting membrane 
potential, and cardiac repolarization.[43]  The M3-receptor also interacts with gap-junctional 
channel connexin 43 (Cx43) to maintain cell-cell communication and excitation propagation in the 
heart.[44] Interestingly, Cx43 mutations leading to gap junction loss were implicated previously in 
some cases of SIDS.[24]   In 2010, cardiac muscarinic receptor over-expression in left ventricular 
heart samples was shown to be associated with SIDS.[45]  In 1995, Kinney and colleagues provided 
evidence that deficiency of muscarinic receptor binding in the arcuate nucleus of the medulla may 
be associated with an increase in the probability of death from SIDS.[46]   
LHX9-encoded Lhx9 is a member of the apterous group of the LIM-homeodomain family of 
evolutionary conserved transcription factors crucial for the correct development of many organs 
including the heart and the nervous system, including the forebrain, thalamus, hypothalamus, and 
pineal gland.[47-51]  Sparks and Hunsaker reported a significant reduction in the size of the pineal 
gland in SIDS cases compared to controls.[52]  In mice, Lhx9 expression is maintained after birth 
in the hippocampal formation and restricted to the dentate gyrus.[51]  Recently, Kinney identified 
dentate gyrus abnormalities as a potential developmental vulnerability in sudden unexplained death 
in infants that may lead to autonomic/respiratory instability or autonomic seizures, and sleep-related 
sudden death of the vulnerable infant when exposed to homeostatic stressors.[53, 54]   
Whether NR3C2, CHRM3, LHX9 or any of the other genes that may have an over-
representation of ultra-rare, nonsynonymous variants in SIDS are indeed responsible for the 
pathogenic basis for SIDS will require substantial functional analyses and replication studies before 
being considered as a new pathogenic substrate for some infant deaths.   
The Ingenuity Pathway Analysis has suggested a potential association between the 
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glucocorticoid biosynthesis signaling pathways and SIDS.  Glucocorticoids and mineralocorticoid, 
such as aldosterone and cortisol, are hormones that regulate numerous physiological processes, 
including intermediate metabolism, immune function, and cardiovascular function.[55, 56]  They 
are synthesized and released from the adrenal gland in a circadian manner and in response to stress.  
Nearly 3.5% of the European Caucasian cases had a heterozygote, ultra-rare, non-synonymous 
variant within either the CYP17A1 or CYP11B2 compared to 0.4% of controls.  While the 
CYP17A1-encoded steroid 17-alpha-hydroxylase is involved in the synthesis of cortisol, the 
CYP11B2-encoded aldosterone synthase is involved in the synthesis of aldosterone.[55]  
Aldosterone, through increased activation of the mineralocorticoid receptor, increases calcium 
influx in ventricular myocytes, prolongs ventricular repolarization, and leads to triggered cardiac 
arrhythmias.[57] Additional investigation and replication will be necessary before invoking genetic 
perturbations in glucocorticoid biosynthesis signaling as a potentially novel pathogenic substrate for 
SIDS.  
Conclusions 
From the perspective of ultra-rare genetic variation in the exome, the lack of significant genetic 
associations suggests an extreme heterogeneity of etiologies underlying SIDS. Until or unless some 
of the genes identified herein emerge as true SIDS-susceptibility genes with sufficient monogenic 
penetrance, then monogenic SIDS, stemming from the cardiac channelopathies and other 
established sudden death predisposing pathways, comprises less than 10% of all SIDS.  In other 
words, the vast majority of SIDS is NOT monogenic, at least within the exome.  Whether 
oligo/polygenic models of genetic variation accounting for the “vulnerable infant” will emerge 
remains to be determined.   
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